An interventional study of Bone marrow aspirate concentrate injection and intra-articular injection of Minimally manipulated adipose tissue in Knee Osteoarthritis, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli — 13 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Knee · Istituto Ortopedico Rizzoli.
Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 21 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 19th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →13 of the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–60
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40–65
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 65–80
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–85
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–40
By country, each count listing its studies:
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 204 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 50 across the 25 interventional studies, 105 across the 6 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.
4 of the studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06726629Istituto Ortopedico RizzoliCrosscultural Adaptation And Validation Of The Italian Version Of The New Knee Society Knee Scoring System | 2026-11 |
| NCT06251752Istituto Ortopedico RizzoliLong Term Evaluation of Clinical and Radiologic Results on Femoro-patellar Joint After High Tibial Osteotomy | 2026-12 |
| NCT06040957Istituto Ortopedico RizzoliBone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis | 2027-01 |
| NCT06490770Istituto Ortopedico RizzoliAnalysis of the Pathophysiological and Functional State of the Knee Joint | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The MAST-GR study is a randomized controlled interventional trial with parallel treatment arms and 1:1 allocation
The primary objective of the study is to compare the safety and efficacy of a single intra-articular infiltration of Bone marrow aspirate concentrate (BMAC) with one of minimally manipulated adipose tissue (MM-AT) so as to determine the most effective cellular product in treating patients with knee osteoarthritis (OA).
The secondary objective is to demonstrate whether intra-articular infiltration of BMAC or MM-AT can induce disease-modifying effects in knee OA by imaging and biological assessments on peripheral blood.
The tertiary objective of the study is to identify factors that influence the clinical response to treatment (baseline characteristics of patients, biological characteristics of the treated knee, characteristics of cellular products, BMAC and MM-AT).
Patients with symptomatic unilateral knee OA will be included in a randomized controlled Trial (RCT), in which one group of patients will be treated with 1 intra-articular infiltration of BMAC, and one group will be treated with 1 intra-articular infiltration of MM-AT. A total of 204 patients will be included and will undergo infiltrative treatment after collecting informed consent for study participation and master data. Patients will be clinically evaluated at 0-2-6-12 months follow-up. Possible disease-modifying effects of the two cell products will be investigated by analysis on peripheral blood at 0-2-6-12 months follow-up and by evaluation of radiographic and magnetic resonance imaging (MRI) at 0 and 12 months follow-up. In addition, characterization of the portion of BMAC and MM-AT remaining from treatment will be carried out, as well as baseline assessment of peripheral blood on all patients, and synovial fluid and synovial membrane, where possible, to analyze their influence on clinical outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with symptomatic unilateral knee OA with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized in this group will undergo single knee intra-articular injection of bone marrow aspirate concentrate (BMAC)
Biological: Bone marrow aspirate concentrate injection
Patients randomized in this group will undergo single knee intra-articular injection of minimally manipulated adipose tissue (MM-AT)
Biological: intra-articular injection of Minimally manipulated adipose tissue
single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
Western Ontario and McMaster University Osteoarthritis index (WOMAC) - Pain subscale
It is a pathology-specific questionnaire used for the assessment of referred pain at the knee joint level in patients with OA
Time frame: 6 months follow-up
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
It's a standardized and widely used questionnaire to assess the condition of patients with osteoarthritis of the knee and includes assessment of pain, stiffness, and physical function of the joints. It can be administered to the patient. It measures 5 items for pain (range 0-20), two for stiffness (range 0-8), and 17 for functional limitation (range 0-68) that mainly relate to activities of daily living (e.g., getting up from a sitting position, bending over, going up and down stairs etc.); The score is then normalized on a 0-100 scale. Higher values indicate a worse outcome
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Knee Injury and Osteoarthritis Outcome Score (KOOS)
This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathology. The questionnaire examines the following categories: symptoms, stiffness, pain, daily activities, sports and quality of life
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Visual Analogue Scale (VAS)
Visual analog scale consisting of a straight line segment (10 cm length), the ends of which correspond to "no pain" (0) and "the strongest pain imaginable" (10).
Time frame: baseline, 2 months, 6 months, 12 months follow-up
EuroQol Visual Analogue Scale (EQ-VAS)
EQ-VAS is a visual analog scale that has a range of scores from 0 (worst imaginable health condition) to 100 (best imaginable health condition).
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Tegner Activity Level Scale
Tegner Activity Level Scale is a questionnaire to find out the patient's level of physical activity.All patients will indicate the type of sporting activity performed and its frequency.
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Objective parameters- Range of Motion
Evaluation of the Range of Motion for comparative analysis.
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Objective parameters - Circumferences
Bilateral trans- and supra- patellar circumferences measurement for comparative analysis
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Patient Acceptable Symptom State (PASS)
A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering "yes" or "no.
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Minimally Clinical Important Difference (MCID)
The patient should indicate the degree of perceived improvement after the infiltrative procedure.
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Expectations about the effectiveness of the treatment
The patient should indicate at baseline what clinical benefits he or she expects from the treatment according to the question, "What benefits do you expect to get as a result of the treatment you will undergo?" the patient can choose from one of the following items:Full recovery, Definitely better, Much better, Slightly better,No change
Time frame: baseline
Kellgren-Lawrence score
The Kellgren Lawrence scale classifies knee OA into 4 grades of subsequent greater severity, the parameters used being reduced joint space and the presence of osteophytes
Time frame: baseline, 12 months follow-up
3 Tesla Nuclear Magnetic Resonance Imaging (3T MRI)
Sequences such as T2-weighted FSE, FS-3D SPGR, and T2 Mapping will be used to assess cartilage thickness and signal, the presence of cysts and subchondral edema, joint profile, the presence of osteophytes and their size, the status of the menisci, both medial and lateral, and the status of the synovium.
Time frame: baseline, 12 months follow-up
Analysis of circulating micro RNAs
miRNAs, involved in OA progression, will be identified and quantified, including miR675-5p, miR-31-5p and miR-33a-5p
Time frame: baseline, 2 months, 6 months, 12 months follow-up
Plan to share: No — We will be able to share a subset of aggregated data, wich will not allow for the identification of participants
Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 36 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.